Metformin and thiazolidinedione use in Medicare patients with heart failure.
about
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic reviewUse of metformin in diseases of agingMetformin and metabolic diseases: a focus on hepatic aspectsA review of cardiovascular risks associated with medications used to treat type-2 diabetes mellitus.Metformin protects against systolic overload-induced heart failure independent of AMP-activated protein kinase α2.Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and functionEffects of funding policy changes and health warnings on the use of erythropoiesis-stimulating agentsMedicine utilization review at a university teaching hospital in New Delhi.Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning.Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications?Pioglitazone initiation and subsequent hospitalization for congestive heart failure.Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.Type 2 diabetes mellitus and heart failure.Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality.Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?Rosiglitazone is associated with mortality in chronic hemodialysis patients.Cardiovascular risk of rosiglitazone: another perspective.Glycemic control and diabetes management in hospitalized patients in BrazilAdd-on therapies to metformin for type 2 diabetes.Thiazolidinedione use in elderly patients with type 2 diabetes: with and without heart failure.Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment.Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.Metformin: New Preparations and Nonglycemic Benefits.Management of newly treated diabetes in Medicare beneficiaries with and without heart failure.Metformin monitoring and change in serum creatinine levels in patients undergoing radiologic procedures involving administration of intravenous contrast media.[Adjunctive therapies to glycaemic control of type 1 diabetes mellitus].Fulminant lactic acidosis in two patients with Type 2 diabetes treated with metformin.Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
P2860
Q22242077-1970FEB3-2CCE-441C-8287-5CE3CE625A2EQ26828760-F1F7AE4D-5152-427D-81AA-1B4660540E8AQ28082736-5DCEF238-133D-4E24-8266-FB807A1337E6Q33561396-C5291F88-8FDE-4E4E-92EE-A0B72C812CCAQ33632353-1AF3C697-C499-4EC0-9C90-3C8CA2A60635Q34123775-64BAEB42-D8BE-4514-BDC3-63BC4FF41D74Q36095172-BA6DB367-AE3E-42C3-8244-3A729A209D0EQ36181823-EBE7BE1F-4218-45CE-88CF-50BA83442666Q36320556-78BED136-56C5-4DBA-8407-1DED40D4C56FQ36390892-80E5431F-F3AC-434A-B370-D7EA1057E17FQ36524748-2A8E6D2F-183A-44C1-B4AD-B2A75AAC7D07Q36531654-FCD27470-BB0B-4444-929A-E8E0313DDD7CQ36570644-FDB0FC01-DFD1-43E1-B543-1245CCC78A21Q36716456-EAF34702-BEF7-49DE-B618-950F14B2204FQ37069176-D1E2DCBD-24EE-4C8F-81D9-F80A5D024691Q37069180-581788F0-A7C2-4A13-90EC-583D6E56882BQ37102216-A42009A6-44C9-4D68-9565-6D6AD00F9349Q37107490-23BBFC27-8A3F-4B6D-B6A9-80C750FC4A97Q37181975-18F0C06D-0DB8-4941-AE9B-1D83ECE6370DQ37322689-320D4B5A-98FC-4EAA-A744-540505773A37Q37376834-CA631622-8E77-43F0-AF76-D3CA5B9A781DQ37818234-09B88EAB-F0DE-4E55-9463-CD54C06C2534Q37844021-FA812485-2AAE-4040-A388-A537FE190878Q37882500-C7B4C506-FBF5-4178-B166-49FDF2E4BF91Q38836416-3D4E827D-5638-4E3C-900E-8FD2B9B28554Q39100209-013B4465-46C9-496A-8285-0C325E036E72Q39247252-DA508757-592D-46CE-9F91-C3BEDE0AF60EQ45037776-51E48168-C98E-4CEC-90D0-BCCF8331EF0DQ46625434-715BD7B4-102E-4BD9-984C-2C91C1D8F83FQ46714495-21C6E796-F92F-4998-A964-1E50E8F185E8Q46721366-58FB8383-DF07-4115-92B3-2FD1EAD28177Q46959411-0D7B8AE3-8AD4-4DDE-906B-CFAA3438F1AB
P2860
Metformin and thiazolidinedione use in Medicare patients with heart failure.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Metformin and thiazolidinedione use in Medicare patients with heart failure.
@ast
Metformin and thiazolidinedione use in Medicare patients with heart failure.
@en
Metformin and thiazolidinedione use in Medicare patients with heart failure.
@nl
type
label
Metformin and thiazolidinedione use in Medicare patients with heart failure.
@ast
Metformin and thiazolidinedione use in Medicare patients with heart failure.
@en
Metformin and thiazolidinedione use in Medicare patients with heart failure.
@nl
prefLabel
Metformin and thiazolidinedione use in Medicare patients with heart failure.
@ast
Metformin and thiazolidinedione use in Medicare patients with heart failure.
@en
Metformin and thiazolidinedione use in Medicare patients with heart failure.
@nl
P2093
P356
P1476
Metformin and thiazolidinedione use in Medicare patients with heart failure.
@en
P2093
Edward P Havranek
JoAnne M Foody
John F Setaro
Silvio E Inzucchi
Yongfei Wang
P356
10.1001/JAMA.290.1.81
P407
P577
2003-07-01T00:00:00Z